FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology
“We are excited to announce that FG-3246 in combination with enzalutamide in patients with mCRPC demonstrated clinically meaningful early signals of efficacy,” commented Deyaa Adib, M.D., Chief Medical Officer of FibroGen.
- “We are excited to announce that FG-3246 in combination with enzalutamide in patients with mCRPC demonstrated clinically meaningful early signals of efficacy,” commented Deyaa Adib, M.D., Chief Medical Officer of FibroGen.
- Over 70% of the patients in the study received at least two prior ARSIs, which included prior enzalutamide treatment.
- The primary endpoint was determination of the maximally tolerated dose (MTD) of FG-3246 in combination with enzalutamide.
- The MTD was established at 2.1 mg/kg ABW, with primary G-CSF prophylaxis, in combination with enzalutamide 160 mg/day.